Truist's Downgrade of Doximity#
Truist Securities has downgraded Doximity Inc (NYSE:DOCS) from a Buy rating to Hold. This change comes as the firm expresses concerns over the company's revenue growth visibility and increasing structural risks. The new price target for Doximity has been set at $29, down from a previous target of $37. Currently, the stock is trading at $24.71, which is about 67% lower than its 52-week high of $76.51.
Factors Behind the Downgrade#
The downgrade follows Doximity's announcement of the resignation of its Chief Financial Officer, Anna Bryson, who had been on medical leave since February. Truist highlighted a lack of clarity regarding pharmaceutical digital marketing budgets and anticipates that Doximity's growth for fiscal year 2027 will fall short of market expectations. Additionally, the firm noted that the healthcare information technology sector is experiencing multiple compression, which refers to a decrease in the price-to-earnings ratios of stocks in this industry.
Competitive Pressures and Analyst Sentiment#
Truist pointed out that Doximity is facing emerging competition from AI-driven platforms like OpenEvidence. The firm expects Doximity's management to adopt a cautious approach when providing guidance for fiscal year 2027. This sentiment is echoed by a broader trend among analysts, with 17 analysts revising their earnings forecasts downward for the upcoming period. Doximity's stock has seen a significant decline of 63.66% over the past six months.
Other Analyst Updates#
In addition to Truist's downgrade, other analysts have also adjusted their views on Doximity. BofA Securities lowered its price target from $56 to $47 but maintained a Buy rating, citing mixed yet positive survey results. Evercore ISI downgraded Doximity to In Line from Outperform, reducing its price target to $25 due to slower market growth and heightened competitive risks. Meanwhile, Freedom Capital Markets initiated coverage with a Buy rating and set a price target of $31, focusing on future revenue and earnings projections. These varied perspectives illustrate the differing views on Doximity's market position and growth potential.